Published in MAGMA on August 28, 2008
Choline PET for monitoring early tumor response to photodynamic therapy. J Nucl Med (2009) 1.15
The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach. Cancer Biomark (2008) 1.00
Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging (2009) 0.84
Neuropeptide Y (NPY) in tumor growth and progression: Lessons learned from pediatric oncology. Neuropeptides (2015) 0.75
Dimensionality reduction-based fusion approaches for imaging and non-imaging biomedical data: concepts, workflow, and use-cases. BMC Med Imaging (2017) 0.75
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol (2006) 13.13
Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med (2002) 8.04
Angiogenesis. Annu Rev Med (2006) 6.94
Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging (1997) 6.77
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology (2001) 3.99
Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA (1993) 3.46
Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol (2007) 3.17
Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol (2006) 2.72
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Studies of human tumors by MRS: a review. NMR Biomed (1993) 2.44
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol (2001) 2.32
Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun (2002) 2.09
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol (2007) 1.99
Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer (2007) 1.72
Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat Med (1997) 1.69
Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. Radiology (2007) 1.67
Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res (1998) 1.62
Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn (2006) 1.54
Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest (2003) 1.52
Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst (2003) 1.46
Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res (1996) 1.42
Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol (2007) 1.41
Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med (2006) 1.38
Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med (2006) 1.33
Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol (2007) 1.28
Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci U S A (2003) 1.28
Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol (2003) 1.27
Molecular imaging of antiangiogenic agents. Oncologist (2005) 1.25
Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol (2003) 1.18
Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T. Magn Reson Med (2005) 1.17
Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol (2006) 1.15
Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia (2001) 1.14
Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res (2005) 1.11
3 Tesla magnetic resonance imaging of the prostate with combined pelvic phased-array and endorectal coils; Initial experience(1). Acad Radiol (2004) 1.09
Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol (2005) 1.07
3T MR of the prostate: reducing susceptibility gradients by inflating the endorectal coil with a barium sulfate suspension. Magn Reson Med (2007) 1.04
Parametric analysis of breast MRI. J Comput Assist Tomogr (2002) 1.03
Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides (2003) 1.03
Angiogenesis imaging in the management of prostate cancer. Nat Clin Pract Urol (2005) 0.98
Magnetic resonance imaging and magnetic resonance spectroscopic imaging of prostate cancer. Nat Clin Pract Urol (2005) 0.98
Tissue-print and print-phoresis as platform technologies for the molecular analysis of human surgical specimens: mapping tumor invasion of the prostate capsule. Nat Med (2004) 0.98
Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology (2006) 0.97
Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol Biomarkers Prev (2006) 0.97
Neuropeptide Y: a novel mechanism for ischemic angiogenesis. Trends Cardiovasc Med (2003) 0.95
Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension. BMC Cancer (2005) 0.92
Synthesis and release of ( 14 C)acetylcholine in synaptosomes. J Neurochem (1971) 0.87
3D MR spectroscopic imaging in the evaluation of prostate cancer. Clin Radiol (2007) 0.87
Modulatory actions of neuropeptide Y on prostate cancer growth: role of MAP kinase/ERK 1/2 activation. Adv Exp Med Biol (2007) 0.86
Distribution of vascular endothelial growth factor (VEGF) in prostate disease. Prostate Cancer Prostatic Dis (2002) 0.84
Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging. Abdom Imaging (2007) 0.82
Neuropeptide Y (NPY) in neuroblastoma: effect on growth and vascularization. Peptides (2007) 0.77
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Renal clearance of quantum dots. Nat Biotechnol (2007) 12.54
Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol (2003) 11.09
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol (2009) 6.15
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Initiation of myoblast to brown fat switch by a PRDM16-C/EBP-beta transcriptional complex. Nature (2009) 4.98
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol (2009) 4.06
Selection of quantum dot wavelengths for biomedical assays and imaging. Mol Imaging (2003) 4.01
Image-guided oncologic surgery using invisible light: completed pre-clinical development for sentinel lymph node mapping. Ann Surg Oncol (2006) 3.98
Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation. Mol Imaging (2010) 3.88
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst (2003) 3.73
Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (2010) 3.66
MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology (2004) 3.59
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol (2006) 3.39
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
Functional near-infrared fluorescence imaging for cardiac surgery and targeted gene therapy. Mol Imaging (2002) 3.37
The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol (2011) 3.24
Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst (2003) 3.19
Organic alternatives to quantum dots for intraoperative near-infrared fluorescent sentinel lymph node mapping. Mol Imaging (2005) 3.19
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer (2009) 3.03
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol (2013) 3.01
14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol (2002) 2.97
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol (2009) 2.94
ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol (2009) 2.91
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol (2010) 2.85
FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biol (2010) 2.79
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Quantitation of brown adipose tissue perfusion in transgenic mice using near-infrared fluorescence imaging. Mol Imaging (2003) 2.68
Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer. Ann Surg Oncol (2011) 2.67
Size series of small indium arsenide-zinc selenide core-shell nanocrystals and their application to in vivo imaging. J Am Chem Soc (2006) 2.65
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem (2003) 2.62
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62
E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res (2003) 2.61
Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol (2010) 2.59
JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 2.59
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res (2008) 2.58
Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots. Ann Thorac Surg (2005) 2.52
Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol (2009) 2.51
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res (2009) 2.51
Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res (2010) 2.50
Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. Am J Pathol (2002) 2.50
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther (2009) 2.47
Targeted zwitterionic near-infrared fluorophores for improved optical imaging. Nat Biotechnol (2013) 2.44
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia (2006) 2.39
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol (2012) 2.39
Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett (2009) 2.37